Welcome to our dedicated page for Mannkind news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind stock.
MannKind Corporation (MNKD) specializes in innovative inhaled therapies for diabetes and respiratory diseases, notably through its FDA-approved Afrezza® inhaled insulin. This page aggregates official announcements, clinical trial updates, and strategic partnership news critical for understanding the company's trajectory.
Investors and researchers will find curated press releases covering financial results, regulatory milestones, and technology licensing agreements. The collection emphasizes developments in MannKind's core platforms: the Technosphere® drug delivery system and iSPERSE™ formulation technology.
Content includes updates on pulmonary arterial hypertension treatments, diabetes management solutions, and global expansion initiatives. All materials maintain factual accuracy without speculative analysis, adhering to financial disclosure standards.
Bookmark this page for streamlined access to MNKD's latest business developments and scientific advancements. Verify time-sensitive details directly through company filings or official communications.
MannKind Corporation (MNKD) reported its fourth quarter and full-year 2020 results, highlighting Afrezza net revenue of $10.1 million, a 30% increase year-over-year. Total revenues for 2020 reached $65.1 million, with Afrezza contributing $32.3 million. The company experienced a net loss of $26.4 million in Q4 and $57.2 million for the year. Gross profit from Afrezza surged 230% to $17.2 million. The acquisition of QrumPharma for $12.8 million and entering into a co-promotion agreement for Thyquidity are key strategic moves. Cash reserves stood at $67.2 million at year-end.
Vertice Pharma launched THYQUIDITY, a liquid levothyroxine solution, on February 24, 2021. This product is designed for patients with hypothyroidism, providing precise, individualized dosing. THYQUIDITY will serve as a replacement therapy for various types of hypothyroidism and assist in managing thyroid cancer. The product contains 100 mcg per 5 mL and is supplied in two 100 mL bottles. MannKind Corporation (NASDAQ: MNKD) will co-promote THYQUIDITY to healthcare providers. This marks Vertice's first branded pharmaceutical product aimed at improving patient health.
MannKind Corporation (Nasdaq: MNKD) will have its CEO, Michael Castagna, PharmD, participate in a Fireside Chat at the 2021 SVB Leerink Global Healthcare Conference on February 25, 2021, at 1:00 pm (ET). Interested individuals can access the webcast through the Company's website, with a replay available for 14 days post-event. MannKind is known for developing inhaled therapeutic products, including Afrezza® (insulin human) Inhalation Powder, the only FDA-approved inhaled ultra rapid-acting mealtime insulin in the U.S.
MannKind Corporation (NASDAQ:MNKD) is set to release its 2020 fourth quarter and full year financial results on February 25, 2021, at 9:00 AM ET. The call, featuring CEO Michael Castagna and CFO Steven Binder, will discuss financials and corporate updates. Investors can participate via the company's website or by telephone, with a replay available for 14 days post-call. MannKind focuses on inhaled therapeutic products, commercializing Afrezza, the only FDA-approved inhaled insulin in the U.S., which is also available in Brazil through partner Biomm SA.
MannKind Corporation (Nasdaq: MNKD) announced that its CEO, Michael Castagna, will participate in a Fireside Chat at the H.C. Wainwright Bioconnect 2021 Conference. This event will be available on demand starting January 11, 2021, at 6:00 am (ET). Interested viewers can access the webcast link from the Events & Presentations section on MannKind's website. The replay will remain accessible for 14 days post-event. MannKind specializes in inhaled therapies for endocrine and orphan lung diseases, including Afrezza, the only inhaled ultra rapid-acting mealtime insulin in the U.S.
MannKind Corporation (Nasdaq: MNKD) and Vertice Pharma announced a co-promotion agreement for Thyquidity™ (levothyroxine sodium) oral solution, aimed at treating hypothyroidism. MannKind's sales force will market Thyquidity to US healthcare providers specializing in endocrinology. Vertice will compensate MannKind with quarterly payments and royalties on sales. Michael Castagna, CEO of MannKind, emphasized the arrangement's potential to enhance customer relationships and extend market reach. Thyquidity is indicated for various forms of hypothyroidism, which affects approximately 4.6% of the US population.
MannKind Corporation (Nasdaq: MNKD) has appointed James S. Shannon, M.D., as the new Chairman of the Board effective December 9, 2020. He succeeds Kent Kresa, who remains as a Board member and Chair of the Compensation Committee. Dr. Shannon brings over 20 years of pharmaceutical leadership experience, previously serving as Chief Medical Officer at GlaxoSmithKline and leading Pharma Development at Novartis. This leadership change aims to strengthen MannKind's focus on its pipeline and innovative therapies for endocrine and orphan lung diseases.
MannKind Corporation (Nasdaq: MNKD) has acquired QrumPharma, Inc., a firm focused on inhalation therapies for severe pulmonary infections, including Nontuberculous Mycobacterial (NTM) lung disease. The acquisition includes $3.5 million in cash and 3,067,179 shares of MNKD. The lead product, QRM-003, is set to enter Phase 1 trials by late 2021 and has received FDA orphan drug and QIDP designations. This deal aims to enhance MannKind's pipeline in orphan lung disease treatments and leverage advanced inhalation technologies.
MannKind Corporation (Nasdaq: MNKD) has amended its credit agreement with MidCap Financial Trust, securing $10 million immediately and an additional $25 million contingent upon FDA approval of Treprostinil Technosphere (TreT). The interest-only period extends to September 1, 2022. Key objectives include growing Afrezza as a standard of care for mealtime insulin and advancing TreT toward NDA submission. The amendment also adjusts financial covenants linked to Afrezza's revenue and mandates TreT marketing if Tranche 3 is funded.
MannKind Corporation (NASDAQ: MNKD) announced the appointment of Sabrina Kay, Ed.D., to its Board of Directors, effective December 1, 2020. Dr. Kay will also join the Audit Committee, bringing extensive experience in marketing, finance, and executive leadership. Currently the CEO of Fremont Private Investments, she has successfully managed several companies and is involved in numerous philanthropic initiatives. With Dr. Kay's appointment, MannKind aims to enhance its strategic vision and leadership as it continues to develop its inhaled therapeutic products, including Afrezza.